Investors should monitor the upcoming FDA Type B meeting in Q2 2026 for confirmation of Phase 3 trial design, which will be a key catalyst. The compelling efficacy and tolerability data position aleniglipron as a leading oral GLP-1 candidate, potentially reducing reliance on injectables and expanding market access.
Price Chart
Executive Summary
Structure Therapeutics announced positive Phase 2 results for aleniglipron, an oral GLP-1 receptor agonist, showing placebo-adjusted weight loss of up to 16.3% (39 lbs) at 44 weeks — the highest reported efficacy among oral GLP-1RAs and comparable to injectable versions. The data support advancement into Phase 3 trials, with an FDA end-of-Phase 2 meeting scheduled for Q2 2026 and trial initiation expected in H2 2026.
Key Facts
- Aleniglipron achieved placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks in the ACCESS II study (p<0.0001).
- In the open-label extension, weight loss reached up to 16.2% (40.5 lbs) at 56 weeks with no evidence of plateau.
- Low discontinuation rates (2.0–3.4%) due to adverse events with the 2.5 mg starting dose support improved tolerability.
- Phase 3 initiation remains on track for second half of 2026, following an FDA End-of-Phase 2 meeting in Q2 2026.
- No drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation observed across >625 participants.
Financial Impact
High potential commercial value given best-in-class oral GLP-1RA profile with injectable-like efficacy; could capture significant share of multi-billion-dollar obesity market.
Risk Factors
- Phase 3 trial delays or design changes following FDA feedback.
- Lack of head-to-head comparison with leading injectable GLP-1s like semaglutide or tirzepatide.
- Potential shift in safety or efficacy profile in larger, longer-term studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256111 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | $43.30 $47.34 | ▼ −9.33% | ▼ −4.93% | $27.67 (+36.10%) |
May 7, 2026 21w ago | 8-K | $39.10 $49.64 | ▲ +26.96% | ▲ +22.12% | $27.67 (−29.23%) |
Apr 27, 2026 22w ago | Press Release | $43.56 $50.80 | ▲ +16.62% | ▲ +12.63% | $27.67 (−36.48%) |
Apr 15, 2026 24w ago | 8-K | $54.25 $53.36 | ▼ −1.64% | ▼ −9.78% | $27.67 (−49.00%) |
Mar 16, 2026 28w ago | Press Release | $56.65 $37.77 | ▼ −33.33% | ▼ −43.81% | $27.67 (−51.16%) |
Feb 28, 2026 30w ago | Institutional Cluster | $62.90 $39.58 | ▼ −37.07% | ▼ −46.40% | $27.67 (−56.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access